# Ohad Hammer

> Ohad Hammer is a Series A investor at Pontifax (Tel Aviv) backing Biotechnology and Health Care. See 19 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pontifax](https://shizune.co/investors/profile/pontifax)
- Location: Tel Aviv, Israel
- Total investments: 19
- Last investment: Apr 2026
- Lead investor: 21%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ohad-hammer-2616463/

Ohad Hammer is a Series A investor at Pontifax in Tel Aviv focused on Biotechnology and Health Care. Ohad Hammer - Partner @ Pontifax

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 37% |
| Health Care | 4 | 21% |
| Therapeutics | 2 | 11% |
| Pharmaceutical | 2 | 11% |
| Fitness | 1 | 5% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 37% |
| Series B | 6 | 32% |
| Series C | 3 | 16% |
| Seed | 1 | 5% |
| Post-IPO Equity | 1 | 5% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 3 | 16% |
| Belgium | 2 | 11% |
| Israel | 1 | 5% |
| Denmark | 1 | 5% |
| Germany | 1 | 5% |

7 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M | Series C | Apr 14, 2026 |  |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M | Series A | Oct 16, 2025 |  |
| Step Pharma | Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M | Series C | Oct 15, 2025 |  |
| Kamari Pharma | Kamari Pharma develops innovative treatments for unmet needs and rare diseases in dermatology. | $23M | Series A | Jun 03, 2025 |  |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $135M | Series B | Nov 25, 2024 |  |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $32.2M | Seed | Jun 11, 2024 |  |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $17.3M | Series A | May 29, 2024 |  |
| Climb Bio | Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $120M | Post-IPO Equity | Apr 11, 2024 |  |
| AgomAb Therapeutics | AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $100.8M | Series C | Oct 11, 2023 |  |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $34M | Series A | Apr 04, 2023 |  |

10 of 19 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 9 deals together
- [Dawn Biopharma](https://shizune.co/investors/profile/dawn-biopharma) — VC Fund, 7 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 7 deals together
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 6 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 6 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 5 deals together

## About Pontifax

VC Fund · Herzliya, Israel

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

4 contacts available at Pontifax.

| Name | Title | Profile |
| --- | --- | --- |
| Ohad Hammer | Partner | https://shizune.co/investors/profile/ohad-hammer |
| Ran Nussbaum | Managing Partner and Co-Founder | https://shizune.co/investors/profile/ran-nussbaum |
| Tomer Kariv | Co-Founder and Chief Executive Officer | https://shizune.co/investors/profile/tomer-kariv |
| Momi Karako | Partner | https://shizune.co/investors/profile/momi-karako |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ohad Hammer invest in?

Ohad Hammer invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 19 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ohad Hammer last invest?

The most recent investment recorded for Ohad Hammer closed in Apr 2026. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co